Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy

Diabetes

Volumn 58, Issue 6, 2009, Pages 1373-1381

  Westermann, Dirk ^a   Walther, Thomas ^a   Savvatis, Konstantinos ^a   Escher, Felcicitas ^a   Sobirey, Meike ^a   Riad, Alexander ^a   Bader, Michael ^b   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B1 RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE B; KININ; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; CELL INVASION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GENE DELETION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HYPERGLYCEMIA; INFLAMMATION; KNOCKOUT MOUSE; MORTALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; PROTEIN CONTENT; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION REGULATION;

ANIMALS; BLOOD PRESSURE; CARDIOMYOPATHIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GENE DELETION; HEART; HEART DISEASES; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, BRADYKININ B1; VENTRICULAR FUNCTION, LEFT;

EID: 66649088302     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0329     Document Type: Article

References (52)

1. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006;98:596-605 (Pubitemid 43755278)
2. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007;56:641-646 (Pubitemid 46348458)
3. Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML. Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes 2008;57:2158-2166
4. Dorenkamp M, Riad A, Stiehl S, Spillmann F, Westermann D, Du J, Pauschinger M, Noutsias M, Adams V, Schultheiss HP, Tschope C. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism. Eur J Pharmacol 2005;520: 179-187
5. Li J, Leschka S, Rutschow S, Schwimmbeck PL, Husmann L, Noutsias M, Westermann D, Poller W, Zeichhardt H, Klingel K, Tschope C, Schultheiss HP, Pauschinger M. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur J Pharmacol 2007;554:60-68 (Pubitemid 44820040)
6. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschope C: Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2007;102:500-507 (Pubitemid 47578394)
7. Yoshida H, Zhang JJ, Chao L, Chao J. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 2000;35:25-31 (Pubitemid 30054232)
8. Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L, Chao J. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res 2007;73:130-142 (Pubitemid 44937189)
9. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003;285:H1479-H1488 (Pubitemid 37169501)
10. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M: Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 19:2057-2059, 2005 (Pubitemid 41759764)
11. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang ZR, Chao L. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 2008;52:715-720
12. Cayla C, Todiras M, Iliescu R, Saul VV, Gross V, Pilz B, Chai G, Merino VF, Pesquero JB, Baltatu OC, Bader M. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007;21:1689-1698 (Pubitemid 46855614)
13. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T, Oliveira SM, Pesquero JL, Paiva AC, Calixto JB, Lewin GR, Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 2000;97:8140-8145 (Pubitemid 30460786)
14. Spillmann F, Altmann C, Scheeler M, Barbosa M, Westermann D, Schultheiss HP, Walther T, Tschope C. Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload- induced cardiomyopathy. Int Immunopharmacol 2002;2:1823-1832 (Pubitemid 35373923)
15. Liesmaa I, Kuoppala A, Shiota N, Kokkonen JO, Kostner K, Mayranpaa M, Kovanen PT, Lindstedt KA. Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts. Am J Physiol Heart Circ Physiol 2005;288:H2317-H2322 (Pubitemid 40604120)
16. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, Pesquero JB, Bader M, Madeddu P. Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 2002;105:360-366
17. Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, Liu YH, Liao TD, Yang JJ, Bader M, Yang XP. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 2005;45:747-753 (Pubitemid 40418376)
18. Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003;278:219-225 (Pubitemid 36043565)
19. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 2007;28:1383-1389 (Pubitemid 47088743)
20. Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M, Potter JD, Schultheiss HP, Tschope C. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail 2006;8:115-121 (Pubitemid 43240843)
21. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051-2060
22. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschope C. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008;52:1068-1075
23. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bucker- Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschope C. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007;56:1834-1841 (Pubitemid 47025453)
24. Howarth FC, Jacobson M, Shafiullah M, Adeghate E. Effects of insulin treatment on heart rhythm, body temperature and physical activity in streptozotocin-induced diabetic rat. Clin Exp Pharmacol Physiol 2006;33: 327-331
25. Emanueli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L, Madeddu P. Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 2002;106:993-999
26. Montanari D, Yin H, Dobrzynski E, Agata J, Yoshida H, Chao J, Chao L. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 2005;54: 1573-1580 (Pubitemid 40586692)
27. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept 2007;140:12-20 (Pubitemid 46275053)
28. Koch M, Spillmann F, Dendorfer A, Westermann D, Altmann C, Sahabi M, Linthout SV, Bader M, Walther T, Schultheiss HP, Tschope C. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur J Pharmacol 2006;550:143-148 (Pubitemid 44574499)
29. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002; 40:653-659 (Pubitemid 35278601)
30. Tschope C, Spillmann F, Rehfeld U, Koch M, Westermann D, Altmann C, Dendorfer A, Walther T, Bader M, Paul M, Schultheiss HP, Vetter R. Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J 2004;18:1967-1969 (Pubitemid 39602300)
31. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 2004;18:828-835 (Pubitemid 38544501)
32. Sharma JN, Kesavarao U. Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacology 1996;33: 341-343 (Pubitemid 26247964)
33. Lagneux C, Bader M, Pesquero JB, Demenge P, Ribuot C. Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2002;2:815-822 (Pubitemid 34603126)
34. Gabra BH, Berthiaume N, Sirois P, Nantel F, Battistini B. The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy. Biol Chem 2006;387:127-143 (Pubitemid 43221825)
35. Klein J, Gonzalez J, Duchene J, Esposito L, Pradere JP, Neau E, Delage C, Calise D, Ahluwalia A, Carayon P, Pesquero JB, Bader M, Schanstra JP, Bascands JL. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 2009;23: 134-142
36. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, Renne T, Kleinschnitz C. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009;40:285-293
37. Zhang Y, Adner M, Cardell LO. IL-1beta-induced transcriptional up-regulation of bradykinin B1 and B2 receptors in murine airways. Am J Respir Cell Mol Biol 2007;36:697-705
38. Rodriguez AI, Pereira-Flores K, Hernandez-Salinas R, Boric MP, Velarde V. High glucose increases B1-kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Commun 2006;345:652-659 (Pubitemid 43776984)
39. Gama Landgraf R, Jancar S, Steil AA, Sirois P. Modulation of allergic and immune complex-induced lung inflammation by bradykinin receptor antagonists. Inflamm Res 2004;53:78-83 (Pubitemid 38223373)
40. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 2008;51:1352-1357
41. Westermann D, Lettau O, Sobirey M, Riad A, Bader M, Schultheiss HP, Tschope C. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. Biol Chem 2008;389:713-718
42. Xu J, Carretero OA, Shesely EG, Rhaleb NE, Yang JJ, Bader M, Yang XP. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol 2008;94:322-329
43. Ganju P, Davis A, Patel S, Nunez X, Fox A. p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia. Eur J Pharmacol 2001;421:191-199
44. Lu G, Kang YJ, Han J, Herschman HR, Stefani E, Wang Y. TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J Biol Chem 2006;281:6087-6095 (Pubitemid 43847710)
45. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, Riad A, Pauschinger M, Schultheiss HP, Tschope C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006;49:2507-2513 (Pubitemid 44359113)
46. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2004;54 (Suppl. 2):S114-S124
47. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-498 (Pubitemid 47064570)
48. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandekerckhove J, Libert C. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001;7:1202-1208 (Pubitemid 33063775)
49. Hsieh HL, Yen MH, Jou MJ, Yang CM. Intracellular signalings underlying bradykinin-induced matrix metalloproteinase-9 expression in rat brain astrocyte-1. Cell Signal 2004;16:1163-1176 (Pubitemid 38900519)
50. Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J Immunol 2007;179:4849-4856
51. Ricupero DA, Romero JR, Rishikof DC, Goldstein RH. Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 2000;275:12475-12480 (Pubitemid 30241390)
52. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006;113: 544-554 (Pubitemid 43754355)